H.C. Wainwright Have $6 Target On Heat Biologics (NASDAQ:HTBX).

June 27, 2018 - By Ira Colvard

What Price Target Has H.C. Wainwright Given Heat Biologics (NASDAQ:HTBX)

Investment firm H.C. Wainwright has begun coverage of HTBX’s shares on Tuesday, 26 June. H.C. Wainwright’s Equities researchers have placed Buy rating while setting the TP at $6.

Ticker’s shares touched $2.26 during the last trading session after 1.80% change.Currently Heat Biologics, Inc. is downtrending after 68.71% change in last June 27, 2017. HTBX has 948,799 shares volume. HTBX underperformed by 81.28% the S&P500.

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States.The firm is valued at $47.03 million. The company's T-cell activating platform produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.Last it reported negative earnings. The Company’s TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment.

Another two news for Heat Biologics, Inc. (NASDAQ:HTBX) were briefly released by: Streetinsider.com on June 26, 2018 with title “HC Wainwright Starts Heat Biologics (HTBX) at Buy”. The other Benzinga.com‘s article was titled “Benzinga’s Top Upgrades, Downgrades For June 26, 2018” and released on June 26, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.